A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

  • STATUS
    Recruiting
  • End date
    Aug 10, 2022
  • participants needed
    100
  • sponsor
    Pfizer
Updated on 25 February 2021
lipase
kinase inhibitor
serum bilirubin level
KIT
metastasis
neutrophil count
follicle stimulating hormone
cancer chemotherapy
crizotinib
kidney function test
lung carcinoma
secondary malignant neoplasm of liver

Summary

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

Description

This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy.

  • (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor.
  • (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.

Details
Condition Non-Small Cell Lung Cancer
Treatment Lorlatinib
Clinical Study IdentifierNCT03909971
SponsorPfizer
Last Modified on25 February 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note